Fresenius Kabi has just received approval from Anvisa (Brazilian Health Regulatory Agency) for Tyenne, the first tocilizumab biosimilar on the Brazilian market.
With Tyenne, Fresenius Kabi strengthens its position in the biological drugs market. Tocilizumab is widely used to treat conditions such as rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis (polyarticular and systemic forms), and cytokine release syndrome.
The launch is the result of a global expansion strategy by Fresenius Kabi Biopharma, which has invested heavily in innovation, local production, and long-term partnerships with healthcare institutions in Brazil. In recent years, the company has invested in infrastructure, clinical research, and technical training—placing the country at the center of its strategic operations in Latin America.
In addition to commercial aspects, the company highlights the social impact of introducing Tyenne to the domestic market. Greater accessibility to immunobiological therapies can significantly expand treatment options in public hospitals, rheumatology clinics, and specialized centers, positively impacting thousands of lives.
Fresenius Kabi is already planning new biosimilar launches in the coming years, expanding its operations in the areas of oncology, hematology, and autoimmune diseases.
CC: Anápolis unit/Fresenius Kabi